In addition, the employment in cancer therapy of human antibodies to either CD20 or HER2+ have shown to improve the outcome of CD20+ B lymphoproliferative diseases as non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL) or HER2+ breast adenocarcinomas respectively [12], [13]. Here, ERBB2 is linked to breast adenocarcinoma.